You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

CLINICAL TRIALS PROFILE FOR CHYMOTRYPSIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Chymotrypsin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002311 ↗ The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients Completed Mucos Pharma GmbH and Co Phase 1 1969-12-31 To study the safety and efficacy of four different doses of Wobenzym (an enzyme combination consisting of pancreatin, papain, bromelain, trypsin, lipase, amylase, chymotrypsin, and rutin) in patients with HIV infection whose CD4 count is between 250 and 400 cells/mm3. To evaluate the effect of Wobenzym on certain surrogate markers associated with progression of HIV disease.
NCT00374699 ↗ Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas Completed Janssen Medical Affairs Phase 1/Phase 2 2006-04-01 Peripheral T-cell lymphomas (PTCLs) are neoplasias from post-thymic T-cells at different stages of differentiation and are a heterogeneous group of malignancies which present with different morphological patterns, phenotypes, and clinical presentations. These tumours have a striking epidemiological distribution with a lower incidence in Western countries than in Asia. In Korea, PTCLs including T- or natural killer (NK)-cell lymphomas constitute approximately 25 to 35% of all non-Hodgkin's lymphomas. This incidence is quite similar to that of other Eastern Asian countries, including Japan, Hong Kong, and China. Recent studies suggest that the T-cell phenotype is an independent significant prognostic factor, with PTCLs having one of the lowest overall survival and failure-free survival rates. Based on the investigator's experience, the overall complete remission rate was 61.2% (95% confidence interval [CI]: 48.5-72.8%) and the 5-year probability of failure-free survival was 33.5%. Median survival of all patients was 45 months (range 0-64+ months) and the 5-year probability of survival was 36.2%. Rassidakis et al. reported that expression of pro-apoptotic proteins BAX and BCL-XS, may explain the poor response of many types of PTCL to standard chemotherapy. To overcome such poor outcome, the optimal therapy for PTCLs remains to be defined. However, because of the rarity of the disease in Western countries, only a few trials have been reported. Bortezomib (Velcade) is a modified dipeptidyl boronic acid, and a reversible inhibitor of the chymotrypsin-like activity of the 26S proteosome. Bortezomib may induce tumor cell apoptosis or decreased bcl-2 associated drug resistance. Through phase II studies, single agent bortezomib in patients with relapsed indolent and mantle cell lymphomas showed its activity. And also preliminary data indicate that bortezomib can be safely administered in combination with dose adjusted etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin (EPOCH) chemotherapy. Therefore, it can be possible to improve the poor outcome of patients with PTCLs by a combination of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) with bortezomib as a first-line therapy. Primary Hypothesis: Based on the clinical trials and experimental data, bortezomib can overcome pro-apoptotic proteins BAX and BCL-XS induced drug resistance.
NCT00374699 ↗ Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas Completed Samsung Medical Center Phase 1/Phase 2 2006-04-01 Peripheral T-cell lymphomas (PTCLs) are neoplasias from post-thymic T-cells at different stages of differentiation and are a heterogeneous group of malignancies which present with different morphological patterns, phenotypes, and clinical presentations. These tumours have a striking epidemiological distribution with a lower incidence in Western countries than in Asia. In Korea, PTCLs including T- or natural killer (NK)-cell lymphomas constitute approximately 25 to 35% of all non-Hodgkin's lymphomas. This incidence is quite similar to that of other Eastern Asian countries, including Japan, Hong Kong, and China. Recent studies suggest that the T-cell phenotype is an independent significant prognostic factor, with PTCLs having one of the lowest overall survival and failure-free survival rates. Based on the investigator's experience, the overall complete remission rate was 61.2% (95% confidence interval [CI]: 48.5-72.8%) and the 5-year probability of failure-free survival was 33.5%. Median survival of all patients was 45 months (range 0-64+ months) and the 5-year probability of survival was 36.2%. Rassidakis et al. reported that expression of pro-apoptotic proteins BAX and BCL-XS, may explain the poor response of many types of PTCL to standard chemotherapy. To overcome such poor outcome, the optimal therapy for PTCLs remains to be defined. However, because of the rarity of the disease in Western countries, only a few trials have been reported. Bortezomib (Velcade) is a modified dipeptidyl boronic acid, and a reversible inhibitor of the chymotrypsin-like activity of the 26S proteosome. Bortezomib may induce tumor cell apoptosis or decreased bcl-2 associated drug resistance. Through phase II studies, single agent bortezomib in patients with relapsed indolent and mantle cell lymphomas showed its activity. And also preliminary data indicate that bortezomib can be safely administered in combination with dose adjusted etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin (EPOCH) chemotherapy. Therefore, it can be possible to improve the poor outcome of patients with PTCLs by a combination of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) with bortezomib as a first-line therapy. Primary Hypothesis: Based on the clinical trials and experimental data, bortezomib can overcome pro-apoptotic proteins BAX and BCL-XS induced drug resistance.
NCT00396864 ↗ Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma Completed Celgene Phase 1 2006-05-01 Multicenter, open-label study of NPI-0052 in patients with advanced solid tumor malignancies or refractory lymphoma whose disease had progressed after treatment with standard, approved therapies that included 2 stages. The initial stage involved dose escalation to an MTD and determination of a recommended Phase 2 dose. The second stage comprised an expansion cohort at the recommended Phase 2 dose.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Chymotrypsin

Condition Name

Condition Name for Chymotrypsin
Intervention Trials
Autism 2
COVID-19 2
Refractory Diffuse Large B-Cell Lymphoma 1
Healthy Volunteers 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Chymotrypsin
Intervention Trials
Lymphoma 3
COVID-19 2
Autistic Disorder 2
Lymphoma, T-Cell 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Chymotrypsin

Trials by Country

Trials by Country for Chymotrypsin
Location Trials
United States 47
United Kingdom 13
Egypt 2
Korea, Republic of 1
Turkey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Chymotrypsin
Location Trials
New York 5
Texas 3
Arizona 3
Rhode Island 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Chymotrypsin

Clinical Trial Phase

Clinical Trial Phase for Chymotrypsin
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Chymotrypsin
Clinical Trial Phase Trials
Completed 7
Active, not recruiting 3
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Chymotrypsin

Sponsor Name

Sponsor Name for Chymotrypsin
Sponsor Trials
Amgen 2
Curemark 2
Ain Shams University 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Chymotrypsin
Sponsor Trials
Other 19
Industry 11
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Chymotrypsin

Introduction to Chymotrypsin

Chymotrypsin is a serine protease enzyme that plays a crucial role in protein digestion and has various applications in medical, research, and industrial fields. Here, we will delve into the current status of clinical trials involving chymotrypsin, analyze its market trends, and provide projections for its future growth.

Clinical Trials Update

Current Clinical Trials

Chymotrypsin is being investigated in several clinical trials for its therapeutic potential in various conditions.

  • Postoperative Care: A notable clinical trial involved the submucosal injection of chymotrypsin to reduce postoperative complications following lower third molar surgery. This randomized, double-blind trial demonstrated the effectiveness and safety of chymotrypsin in reducing swelling, pain, and trismus compared to placebo[4].
  • Other Applications: While specific ongoing trials for chymotrypsin are not extensively detailed, its use in other medical contexts, such as wound healing and anti-inflammatory treatments, is being explored. The enzyme's proteolytic activity makes it a candidate for various therapeutic applications.

Market Analysis

Global Market Size and Growth

The global market for proteolytic enzymes, including chymotrypsin, is experiencing significant growth driven by increasing demand in pharmaceuticals, research, and diagnostics.

  • Current Market Size: The global trypsin market, which is closely related to the chymotrypsin market, was estimated at USD 96.2 million in 2024. Although specific figures for chymotrypsin are not provided, it is part of the broader proteolytic enzyme market[2].
  • Growth Rate: The trypsin market, and by extension the chymotrypsin market, is anticipated to grow at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2030, reaching USD 131.5 million by 2030[2].

Regional Market Outlook

  • North America: This region dominates the global market with a significant share, driven by extensive research and development in biotechnology and pharmaceuticals. Companies like Bio-Rad Laboratories, Creative Enzymes, and Thermo Fisher Scientific are key players in this region[2].
  • Asia Pacific: The market in this region, particularly in China, is growing rapidly due to increasing per capita income, technological advancements, and heightened R&D investment[2].
  • Latin America and MEA: These regions also show high growth potential due to increasing investments in healthcare, growing awareness of enzyme-based therapies, and expanding pharmaceutical industries[2].

Market Drivers

Increasing Demand in Pharmaceuticals

  • Chymotrypsin is widely used in high-throughput screening methods to study protein interactions with potential drug candidates, facilitating the development of novel therapeutics[2].

Rising Incidence of Chronic Diseases

  • The growing incidence of diseases such as cancer, pancreatitis, and cystic fibrosis is driving the demand for diagnostic and therapeutic solutions involving proteolytic enzymes like chymotrypsin[2].

Technological Advancements

  • Advances in enzyme engineering are improving the efficacy and expanding the applications of chymotrypsin beyond healthcare to sectors like food processing and research[2].

Market Challenges

Regulatory Hurdles

  • The development and approval of new therapeutic applications for chymotrypsin must navigate stringent regulatory requirements, which can be a significant challenge.

Competition from Alternative Enzymes

  • The market for proteolytic enzymes is competitive, with other enzymes like trypsin and papain also being used in various applications, which can impact the market share of chymotrypsin.

Projections and Future Outlook

Growing Applications in Cancer Treatment

  • Chymotrypsin, like trypsin, has shown potential tumor-suppressive properties, suggesting its possible use in cancer treatments. This is expected to contribute to the growing demand for chymotrypsin-related studies and therapeutics[2].

Expanding Use in Diagnostic and Therapeutic Solutions

  • The enzyme's role in controlling inflammation and its use in oral hydrolytic enzyme therapies are becoming more important, particularly in regions with high prevalence of chronic diseases[2].

Collaboration and Innovation

  • Increased collaboration between industry and academia, along with technological breakthroughs, is expected to drive innovation and growth in the chymotrypsin market.
"Trypsin is widely used in high-throughput screening methods to study protein interactions with potential drug candidates, facilitating the understanding of structure-function relationships in target proteins, which supports the development of novel therapeutics."[2]

Key Takeaways

  • Chymotrypsin is being investigated in clinical trials for its therapeutic potential, particularly in postoperative care and other medical applications.
  • The global market for proteolytic enzymes, including chymotrypsin, is growing at a CAGR of 5.4% from 2025 to 2030.
  • North America dominates the market, but Asia Pacific and Latin America are emerging as significant growth regions.
  • Increasing demand in pharmaceuticals, rising incidence of chronic diseases, and technological advancements are key market drivers.
  • Regulatory hurdles and competition from other enzymes are notable challenges.

FAQs

What is the current status of clinical trials involving chymotrypsin?

Clinical trials involving chymotrypsin are ongoing, with a notable trial demonstrating its effectiveness in reducing postoperative complications following lower third molar surgery.

What is the projected growth rate of the chymotrypsin market?

The chymotrypsin market, as part of the broader proteolytic enzyme market, is anticipated to grow at a CAGR of 5.4% from 2025 to 2030.

Which regions are driving the growth of the chymotrypsin market?

North America currently dominates the market, but Asia Pacific and Latin America are emerging as significant growth regions due to increasing investments in healthcare and technological advancements.

What are the key drivers of the chymotrypsin market?

Key drivers include increasing demand in pharmaceuticals, the rising incidence of chronic diseases, and technological advancements in enzyme engineering.

What challenges does the chymotrypsin market face?

The market faces regulatory hurdles and competition from other proteolytic enzymes like trypsin and papain.

How is chymotrypsin used in cancer treatment?

Chymotrypsin has shown potential tumor-suppressive properties, suggesting its possible use in cancer treatments, although more research is needed to fully explore this application.

Sources

  1. Clinical Trials Arena: "Pipeline Moves: Novo Nordisk progression prospects drop after..."
  2. Grand View Research: "Trypsin Market Size, Share & Growth Analysis Report, 2030"
  3. MDPI: "3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2"
  4. Frontiers in Oral Health: "Efficacy of Submucosal Injection of Chymotrypsin, Oral..."
  5. Ken Research: "Chymotrypsin Market Research Global Status"

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.